PH12015500785B1 - Novel process for making compounds for use in the treatment of cancer - Google Patents
Novel process for making compounds for use in the treatment of cancerInfo
- Publication number
- PH12015500785B1 PH12015500785B1 PH12015500785A PH12015500785A PH12015500785B1 PH 12015500785 B1 PH12015500785 B1 PH 12015500785B1 PH 12015500785 A PH12015500785 A PH 12015500785A PH 12015500785 A PH12015500785 A PH 12015500785A PH 12015500785 B1 PH12015500785 B1 PH 12015500785B1
- Authority
- PH
- Philippines
- Prior art keywords
- cancer
- treatment
- novel process
- making compounds
- making
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015500785A1 PH12015500785A1 (en) | 2015-06-15 |
| PH12015500785B1 true PH12015500785B1 (en) | 2015-06-15 |
Family
ID=49474740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015500785A PH12015500785B1 (en) | 2012-10-12 | 2015-04-08 | Novel process for making compounds for use in the treatment of cancer |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (OSRAM) |
| EP (1) | EP2909188B1 (OSRAM) |
| JP (2) | JP6300042B2 (OSRAM) |
| KR (1) | KR102204520B1 (OSRAM) |
| CN (2) | CN104837826B (OSRAM) |
| AU (1) | AU2013328929B2 (OSRAM) |
| BR (1) | BR112015008113B1 (OSRAM) |
| CA (1) | CA2889466C (OSRAM) |
| CL (1) | CL2015000926A1 (OSRAM) |
| CR (2) | CR20200237A (OSRAM) |
| EA (1) | EA030613B1 (OSRAM) |
| ES (1) | ES2671502T3 (OSRAM) |
| GE (1) | GEP201706690B (OSRAM) |
| HK (1) | HK1213567A1 (OSRAM) |
| HR (1) | HRP20180670T1 (OSRAM) |
| IL (1) | IL238116B (OSRAM) |
| IN (1) | IN2015DN03928A (OSRAM) |
| MA (1) | MA38085B1 (OSRAM) |
| MX (2) | MX372708B (OSRAM) |
| MY (1) | MY186549A (OSRAM) |
| NZ (1) | NZ706723A (OSRAM) |
| PE (3) | PE20151494A1 (OSRAM) |
| PH (1) | PH12015500785B1 (OSRAM) |
| PL (1) | PL2909188T3 (OSRAM) |
| SA (1) | SA515360271B1 (OSRAM) |
| SG (1) | SG11201502795VA (OSRAM) |
| SI (1) | SI2909188T1 (OSRAM) |
| TR (1) | TR201807861T4 (OSRAM) |
| UA (1) | UA115455C2 (OSRAM) |
| WO (1) | WO2014059422A1 (OSRAM) |
| ZA (1) | ZA201502349B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151494A1 (es) | 2012-10-12 | 2015-11-06 | Exelixis Inc | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EP3316867B1 (en) | 2015-06-30 | 2021-03-10 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| CN109689102A (zh) | 2016-08-12 | 2019-04-26 | 基因泰克公司 | Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法 |
| TW201815419A (zh) | 2016-09-29 | 2018-05-01 | 美商建南德克公司 | Mek抑制劑、 pd-1軸抑制劑及紫杉烷之組合療法 |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| EP4319749A1 (en) | 2021-04-06 | 2024-02-14 | Genentech, Inc. | Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| WO1995026956A1 (fr) | 1994-04-01 | 1995-10-12 | Shionogi & Co., Ltd. | Derive d'oxime et bactericide le contenant en tant qu'ingredient actif |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| AU5610398A (en) | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| DE69836378T2 (de) | 1997-07-01 | 2007-10-11 | Warner-Lambert Co. Llc | Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| HUP0003731A3 (en) | 1997-07-01 | 2002-11-28 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| TR200101704T2 (tr) | 1998-12-15 | 2001-11-21 | Warner-Lambert Company | Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı |
| IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
| EE200100339A (et) | 1998-12-22 | 2002-10-15 | Warner-Lambert Company | Kombineeritud kemoteraapia |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| HUP0104933A3 (en) | 1999-01-07 | 2003-12-29 | Warner Lambert Co | Antiviral method using mek inhibitors |
| US6696440B1 (en) | 1999-01-07 | 2004-02-24 | Warner-Lambert Company | Treatment of asthma with MEK inhibitors |
| NZ513433A (en) | 1999-01-13 | 2003-05-30 | Warner Lambert Co | Benzoheterocycles, their use as MEK inhibitors and use in treating proliferative diseases such as cancer |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| EP1144371B1 (en) | 1999-01-13 | 2005-11-09 | Warner-Lambert Company Llc | Benzenesulphonamide derivatives and their use as mek inhibitors |
| PL348870A1 (en) | 1999-01-13 | 2002-06-17 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
| EP1202726A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| DK1202724T3 (da) | 1999-07-16 | 2004-01-26 | Warner Lambert Co | Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer |
| JP2003504398A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いた慢性疼痛の治療方法 |
| JP2003504399A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| KR100760434B1 (ko) | 1999-09-17 | 2007-10-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 벤즈아미드 및 관련된 Ｘａ 인자의 억제제 |
| WO2001068619A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| NZ524120A (en) | 2000-07-19 | 2005-08-26 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| CZ2003477A3 (cs) * | 2000-08-25 | 2003-10-15 | Warner - Lambert Company Llc | Způsob přípravy N-aryl-anthranilových kyselin a jejich derivátů |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| CN1568184A (zh) | 2001-10-31 | 2005-01-19 | 辉瑞产品公司 | 烟碱乙酰胆碱受体激动剂在治疗多动腿综合征中的用途 |
| WO2003062191A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| PL401637A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| UA76837C2 (uk) | 2002-03-13 | 2006-09-15 | Еррей Байофарма Інк. | N3 алкіловані похідні бензімідазолу як інгібітори мек |
| CA2488567A1 (en) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| AU2003248813A1 (en) | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| EP1606283B1 (en) | 2003-03-03 | 2008-10-08 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| WO2004113347A1 (en) | 2003-06-20 | 2004-12-29 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| DE602004023207D1 (de) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US8084645B2 (en) | 2003-09-19 | 2011-12-27 | Chugai Seiyaku Kabushiki Kaisha | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CA2545659C (en) | 2003-11-19 | 2013-06-04 | Array Biopharma Inc. | Bicyclic inhibitors of mek |
| WO2005058887A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
| TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| BRPI0518192B8 (pt) * | 2004-10-20 | 2021-05-25 | Applied Res Systems Ars Holding N V | derivados de 3-arilamino piridina, seu uso e seu processo de fabricação, e composição farmacêutica |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CA2927656C (en) | 2005-10-07 | 2019-09-24 | Exelixis, Inc. | Mek inhibitors and methods of their use |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| US7999006B2 (en) * | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
| PE20151494A1 (es) | 2012-10-12 | 2015-11-06 | Exelixis Inc | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| AU2014381760B2 (en) | 2014-02-07 | 2018-08-02 | Sumitomo Chemical Company, Limited | Method for producing (R)-1,1,3-trimethyl-4-aminoindane |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en active Application Filing
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 PH PH12015500785A patent/PH12015500785B1/en unknown
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005533A (es) | Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek. | |
| NZ705705A (en) | Ret inhibitor | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| PH12015502284B1 (en) | Protein kinase inhibitors | |
| MA40076A (fr) | Inhibiteurs de syk | |
| PH12015501920B1 (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS | |
| NZ715747A (en) | Syk inhibitors | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| NZ736970A (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2013010050A (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
| IN2014DN00123A (OSRAM) | ||
| IN2014DN10658A (OSRAM) | ||
| IN2014KN01772A (OSRAM) | ||
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| GEP20176633B (en) | Use of pidotimod to treat psoriasis |